Chinese Antibody Society’s Post

📚 Major Histocompatibility complex is a set of genes located on chromosome 6 that play a crucial role in the immune system. While important, it is is difficult to study due to the genetic diversity. 🚀 Good to hear about the MHCepitopes database which contains 451,065 MHC peptide epitopes!

Fight Cancer with Precision Medicines: Antibody Drug Conjugate (ADC) delivery of a cytotoxic drug allows greater specificity than use of the drug alone. This therapeutic modality targets cancer cells while reducing the potential impact on normal cells to improve efficacy and safety. Eurofins Discovery’s OncoPanel® and BioMAP® platforms can aid new ADC therapeutic development! OncoPanel ✔ Supports lead optimization with routine screening using any of our 300+ human tumor cell lines. ✔ Enables the identification of sensitive and resistant tumor types, along with related predictive genomic biomarkers. BioMAP ✔ Generates an actionable phenotypic fingerprint using the Diversity PLUS panel of 12 biological models with 148 clinically relevant protein biomarker readouts. ✔ Enables the identification of broader biological effects and potential toxicity signatures to help de-risk programs by comparison with 4,500+ therapeutic and reference agent profiles. Our experts can help you accelerate & de-risk your ADC program. Contact us today. https://lnkd.in/gDh2fzBP #DrugDiscovery #ADC #EurofinsDiscovery

FDA Grants Accelerated Approval to Ziihera for HER2-Positive Biliary Tract Cancer November 21, 2024 BTC is a devastating disease with a poor prognosis and five-year survival rates under 5% in the metastatic setting. Patients with unresectable or metastatic HER2-positive BTC have had a high unmet need with limited treatment options and few approved therapies. Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii) is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC. Ziihera (zanidatamab-hrii) binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo #researchanddevelopment #innovation #healthcare #lifesciences #fdaapproval #BiliaryTractCancer #cancertreatment

🔬 Researchers from Universitätsklinikum Würzburg published an excellent review on the role of #bispecific antibodies (bsAbs) in patients with cancer. • >200 bsAbs are currently in preclinical or clinical development, but identifying the most appropriate target antigen is a major challenge for successful development. • bsAbs can recruit immune cells near tumors and enable them to thrive due to their ability to overcome the effects of various inhibitory factors and provide stimulatory signals capable of restoring antitumour activity. • Multispecific antibodies targeting two or more pathways may reduce risks of drug resistance and tumour progression compared to monotherapy. • Mitigating cytokine release syndrome by pretreatment with steroids, step-up dosing, subcutaneous administration, modification of CD3ε affinities and prodrug concepts. Find the review here: https://lnkd.in/dAgKGuj2 #Biointron #Antibodies #Bispecific #DrugDevelopment #Oncology #Innovation #Technology #Education #Healthcare #AntibodyProduction

ADCs are medications composed of antibody + Linker + Payload Mainly used in advanced stages of cancer or after failure of mulitple antineoplastics Once ADC in administered, antibody binds to the surface antigen of tumor cell, then the whole ADC is internalized into lysosome, after that payload begin to cleave and diffuse from lysosome into the cell cytoplasm to achieve its cytotoxic effect These medications necessitate some characteristics to be safe and effective based on payload itself (conjugated drug with antibody by linker): 🔷 Sufficient Cytotoxicity inside tumor cells 🔶 Low Immunogenicty through using humanized or small payloads ♦️ High Stability because conjugated antibody remains for a long time in circulation, and to resist low pH in lysosome 🔷Presence of modifiable functional group in payload without affecting potency + Sufficient water solubility to enable conjugation with antibody 🔶 Bystander Kiiling Effect: This Effect enables ADC inside lysosome to spread of lipophilic small molecules disrupting adjacent antigens in the cytoplasm of tumor cells Reference https://lnkd.in/dQaAAHbc

𝗬𝗼𝘂'𝘃𝗲 𝗵𝗲𝗮𝗿𝗱 𝗼𝗳 𝗡𝗞 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆, 𝗯𝘂𝘁 𝘄𝗵𝗮𝘁 𝗮𝗯𝗼𝘂𝘁 𝗴-𝗡𝗞 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆?   g-NK cells are a subset of these 𝙣𝙖𝙩𝙪𝙧𝙖𝙡 𝙠𝙞𝙡𝙡𝙚𝙧𝙨 that lack FcRγ (Fc receptor gamma) receptor proteins. FcRγ proteins help NK cells bind to cancer cells via antibodies as in antibody-dependent cellular cytotoxicity (ADCC). ADCC is a popular mechanism for therapeutics.   Even though g-NK cells can't perform ADCC in the same way, there is evidence that they offer advantages over traditional NK cells in therapy:   🧫Higher levels of cytolytic enzymes and cytokines to destroy cancer cells 🧫Higher antibody-dependent cell-mediated cytotoxicity 🧫Better survival, mobility, and expansion of cells 🧫Can target other, non FcRγ antibody receptors for efficiency   Get the scoop on this emerging technology and its inclusion in a pre-clinical program for Indapta Therapeutics, via a new on-demand webinar: https://lnkd.in/gsyunnnN

Interesting protocol described in this new paper is highly relevant for antibody therapeutics development. From the abstract: This protocol describes two approaches to evaluate dual-cell engagement using flow-based methods which were used previously in our laboratory and are described in Shapir Itai et al. Each approach can be done at a separate time point, and there is no necessity to execute both methods. The read-out from each protocol is different, and their combination will allow a more thorough investigation of cell-cell engagement. This protocol is optimized for HEK293 cells, lymphocytes, and myeloid cells from mouse lymph nodes. Nevertheless, it can be further optimized for a variety of cell types. Results using a bispecific T cell/dendritic cell (DC) immune cell engager (BiCE) are shown, however this protocol can be used using other cell engagers or to measure various markers and cell states within cell-cell doublets in principle. https://lnkd.in/ehHzpAeu

Overcoming the Limitations of Bispecific Antibody Therapy Bispecific antibody therapy is a promising approach to cancer treatment, but it's not without its challenges. To maximize its potential, researchers are exploring these key strategies: 1. Targeted Precision: Identifying unique cancer cell targets to minimize side effects. 2. Optimized Affinity: Balancing antibody binding strength for effective therapy and reduced toxicity. 3. Conditional Activation: Triggering T cell activity only within the tumour microenvironment. 4. Valency Engineering: Modulating antibody structure for enhanced efficacy and safety. 5. Prodrug Design: Activating the drug only at the tumour site. 6. Combination Therapies: Leveraging synergistic effects with other treatments. 7. Patient-Derived Organoids: Accelerating drug development and personalized medicine. Thanks to Hung Trinh for sharing this review. https://lnkd.in/ekPiVAkp https://lnkd.in/eQFpRNd8 If you're interested in discussing your drug development challenges, feel free to connect. #bispecificantibodies #cancertreatment #oncology #drugdevelopment #businessdevelopment #medicalresearch #futureofmedicine

𝗬𝗼𝘂'𝘃𝗲 𝗵𝗲𝗮𝗿𝗱 𝗼𝗳 𝗡𝗞 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆, 𝗯𝘂𝘁 𝘄𝗵𝗮𝘁 𝗮𝗯𝗼𝘂𝘁 𝗴-𝗡𝗞 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆?   g-NK cells are a subset of these 𝙣𝙖𝙩𝙪𝙧𝙖𝙡 𝙠𝙞𝙡𝙡𝙚𝙧𝙨 that lack FcRγ (Fc receptor gamma) receptor proteins. FcRγ proteins help NK cells bind to cancer cells via antibodies as in antibody-dependent cellular cytotoxicity (ADCC). ADCC is a popular mechanism for therapeutics.   Even though g-NK cells can't perform ADCC in the same way, there is evidence that they offer advantages over traditional NK cells in therapy:   🧫Higher levels of cytolytic enzymes and cytokines to destroy cancer cells 🧫Higher antibody-dependent cell-mediated cytotoxicity 🧫Better survival, mobility, and expansion of cells 🧫Can target other, non FcRγ antibody receptors for efficiency   Get the scoop on this emerging technology and its inclusion in a pre-clinical program for Indapta Therapeutics, via a new on-demand webinar: https://lnkd.in/gsyunnnN

Preclinical studies have shed light on potential resistance mechanisms, emphasizing the potential benefit of combinational approaches with other agents such as immune checkpoint inhibitors (ICIs) and targeted tyrosine kinase inhibitors (TKIs) to enhance treatment effectiveness. Additionally, personalized approaches based on molecular profiling hold promise in tailoring ADC treatments to individual tumors, identifying unique molecular markers for each patient to optimize treatment efficacy while minimizing side effects. #antibodydrugconjugate #drugsafety